Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 161 Leukemia 99 Lymphoma, Large B-Cell, Diffuse 94 Precursor Cell Lymphoblastic Leukemia-Lymphoma 92 Lymphoma, Non-Hodgkin 91 Leukemia, Myeloid, Acute 76 Hodgkin Disease 73 Lymphoma, Follicular 63 Burkitt Lymphoma 60 Lymphoma, Mantle-Cell 56 Lymphoma, Large-Cell, Immunoblastic 55 Small Cell Lung Carcinoma 46 Leukemia, Lymphocytic, Chronic, B-Cell 42 Lung Neoplasms 41 Neuroblastoma 40 Lymphoma, B-Cell, Marginal Zone 33 Congenital Abnormalities 33 Multiple Myeloma 30 Recurrence 27 Sarcoma 26 Central Nervous System Neoplasms 26 Carcinoma, Non-Small-Cell Lung 25 Myelodysplastic Syndromes 24 Leukemia, Myelomonocytic, Acute 24 Leukemia, Monocytic, Acute 24 Leukemia, Erythroblastic, Acute 24 Testicular Neoplasms 22 Lymphoma, Large-Cell, Anaplastic 22 Leukemia, Megakaryoblastic, Acute 22 Brain Neoplasms 22

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Malignant Disease × Etoposide × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡